Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia

被引：138
|
作者：
Soverini, Simona [1 ]
Branford, Susan [2 ,3 ,4 ]
Nicolini, Franck E. [1 ,5 ]
Talpaz, Moshe
Deininger, Michael W. N. [6 ]
Martinelli, Giovanni [1 ]
Mueller, Martin C. [7 ]
Radich, Jerald P. [8 ]
Shah, Neil P. [9 ]
机构：
[1] Univ Bologna, S Orsola Malpighi Hosp, Dept Expt Diagnost & Specialty Med, Bologna, Italy
[2] SA Pathol, Dept Mol Pathol, Ctr Canc Biol, Adelaide, SA, Australia
[3] Univ Adelaide, Sch Med, Adelaide, SA, Australia
[4] Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA, Australia
[5] Ctr Hosp Lyon Sud, Hematol Dept 1G, F-69310 Pierre Benite, France
[6] Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[7] Heidelberg Univ, Med Klin 3, Univ Med Mannheim, Mannheim, Germany
[8] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA
[9] Univ Calif San Francisco, Dept Hematol Oncol, San Francisco, CA 94143 USA
来源：
LEUKEMIA RESEARCH | 2014年 / 38卷 / 01期
关键词：
BCR-ABL1; Kinase domain; Tyrosine kinase inhibitors; Philadelphia chromosome; Chronic myeloid leukemia; Resistance; Mutations; DIAGNOSED CHRONIC-PHASE; BCR-ABL MUTATIONS; DASATINIB; 100; MG; PHILADELPHIA-POSITIVE PATIENTS; GIMEMA WORKING PARTY; IMATINIB-RESISTANT; FOLLOW-UP; HIGH-RISK; CML; CHROMOSOME;
D O I：
10.1016/j.leukres.2013.09.011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Patients with chronic myeloid leukemia develop resistance to both first-generation and second-generation tyrosine kinase inhibitors (TKIs) as a result of mutations in the kinase domain (KD) of BCR-ABL1. A wide range of BCR-ABL1 KD mutations that confer resistance to TKIs have been identified, and the T3151 mutant has proven particularly difficult to target. This review summarizes the prevalence impact, and prognostic implications of BCR-ABL1 KD mutations in patients with chronic myeloid leukemia who are treated with current TKIs and provides an overview of recent treatment guidelines and future trends for the detect of mutatkins. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码：10 / 20
页数：11
相关论文
共 50 条
  • [31] Mutations in the BCR-ABL1 kinase domain in patients with chronic myeloid leukaemia treated with TKIs or at diagnosis
    Liu, Jingjing
    Yang, Haiping
    Xu, Xiuwen
    Yi, Shujuan
    Meng, Li
    ONCOLOGY LETTERS, 2020, 20 (02) : 1071 - 1076
  • [32] Distribution of BCR-ABL1 Transcript Variants in Nigerians with Chronic Myeloid Leukemia
    Owojuyigbe, Temilola O.
    Durosinmi, Muheez A.
    Bolarinwa, Ramoni A. A.
    Salawu, Lateef
    Akinola, Norah O.
    Ademosun, Abdulwaheed A.
    Bosede, Oluwayomi T.
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2020, 36 (04) : 646 - 651
  • [33] BCR-ABL1 negative chronic myeloid leukemia: report of two cases
    Figueroa-Faundez, Fernanda
    Vidal-Rojas, Catalina
    Briones-Munoz, Vania
    Chandia-Cabas, Mauricio
    REVISTA MEDICA DE CHILE, 2022, 150 (03) : 397 - 401
  • [34] Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation
    Burslem, George M.
    Schultz, Anna Reister
    Bondeson, Daniel P.
    Eide, Christopher A.
    Stevens, Samantha L. Savage
    Druker, Brian J.
    Crews, Craig M.
    CANCER RESEARCH, 2019, 79 (18) : 4744 - 4753
  • [35] Genetic alterations in the BCR-ABL1 fusion gene related to imatinib resistance in chronic myeloid leukemia
    Martinez-Castillo, Macario
    Gomez-Romero, Laura
    Tovar, Hugo
    Olarte-Carrillo, Irma
    Garcia-Laguna, Anel
    Barranco-Lampon, Gilberto
    De la Cruz-Rosas, Adrian
    Martinez-Tovar, Adolfo
    Hernandez-Zavala, Araceli
    Cordova, Emilio J.
    LEUKEMIA RESEARCH, 2023, 131
  • [36] Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemia
    Trino, Stefania
    De Luca, Luciana
    Simeon, Vittorio
    Laurenzana, Ilaria
    Morano, Annalisa
    Caivano, Antonella
    La Rocca, Francesco
    Pietrantuono, Giuseppe
    Bianchino, Gabriella
    Grieco, Vitina
    Signorino, Elisabetta
    Fragasso, Alberto
    Bochicchio, Maria Teresa
    Venturi, Claudia
    Rosti, Gianantonio
    Martinelli, Giovanni
    Del Vecchio, Luigi
    Cilloni, Daniela
    Musto, Pellegrino
    TUMOR BIOLOGY, 2016, 37 (01) : 217 - 225
  • [37] Analysis of BCR-ABL1 Tyrosine Kinase Domain Mutations In Primitive Chronic Myeloid Leukemia Cells Identifies a Unique Mutator Phenotype
    Jiang, Xiaoyan
    Grant, Hannah
    Stebbing, Justin
    Foroni, Letizia
    Craddock, Charles
    Griffiths, Mike
    Clark, Richard E.
    O'Brien, Stephen
    Khorashad, Jamshid S.
    Gerrard, Gareth
    Wang, Lihui
    Irving, Julie
    Wang, Meng
    Karran, Loraine
    Dyer, Martin J. S.
    Forrest, Donna L.
    Page, Karen
    Eaves, Connie J.
    Woolfson, Adrian
    BLOOD, 2010, 116 (21) : 1390 - 1391
  • [38] Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper
    Simona Soverini
    Elisabetta Abruzzese
    Monica Bocchia
    Massimiliano Bonifacio
    Sara Galimberti
    Antonella Gozzini
    Alessandra Iurlo
    Luigiana Luciano
    Patrizia Pregno
    Gianantonio Rosti
    Giuseppe Saglio
    Fabio Stagno
    Mario Tiribelli
    Paolo Vigneri
    Giovanni Barosi
    Massimo Breccia
    Journal of Hematology & Oncology, 12
  • [39] Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
    O'Hare, Thomas
    Eide, Christopher A.
    Deininger, Michael W. N.
    BLOOD, 2007, 110 (07) : 2242 - 2249
  • [40] Comment on "Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors"
    Kim, Sung-Hyun
    Kim, Dong-Wook
    HAEMATOLOGICA, 2015, 100 (03) : E120 - E121
12345